The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...

Labels of all extended-release stimulants indicated for ADHD -- including certain formulations of amphetamine and ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Children younger than 6 years of age who are prescribed extended-release stimulants for attention-deficit hyperactivity disorder (ADHD) may experience ...

The U.S. Food and Drug Administration said on Monday it is revising the labeling of all extended-release stimulants used to ...

The FDA now requires updated labeling for all extended-release stimulant medications used to treat attention deficit hyperactivity disorder, warning of increased risk of weight loss and other side ...

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...

With semaglutide and tirzepatide dosed once weekly, their estimated average yearly costs in the U.S. are $14,080 and $8,126, ...

GLP-1 drugs bought online or at compound pharmacies could cause harm, according to Tennessee Attorney General Jonathan ...

Agency will require a Limitation of Use section in the prescribing information of all extended-release ADHD stimulants.

The Food and Drug Administration is revising the labeling of all extended-release stimulants used to treat attention-deficit ...